PNW Headlines
Home » Archives for December 2017

Month: December 2017

WednesdayDec 27, 2017 3:49 pm

World Health Organization Officially Rules CBD Should Not be a Scheduled Drug

The World Health Organization (WHO) announced that “the cannabis compound CBD (Cannabidiol) should not be internationally scheduled as a controlled substance” (www.WHO.int) WHO has issued preliminary findings indicating that cannabidiol (CBD) shows “no indications of abuse or dependence potential” and “a good safety profile” MCOA is committed to the development of high quality CBD-based products The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. The CBD pre-review report…

Continue Reading

TuesdayDec 26, 2017 1:08 pm

India Globalization Capital, Inc. (NYSE: IGC) Targets February 2018 International Patent Filing for Eating Disorder Drug

Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation IGC has pre-clinical trial scheduled in 2018 for IGC-AD1, a combination-therapy drug designed to treat Alzheimer’s IGC-506 is a combination therapy developed from cannabis extracts and other compounds that’s designed to treat multiple types of eating disorders in humans and animals India Globalization Capital, Inc. (NYSE American: IGC) (FRA: IGS1) anticipates a Patent Cooperation Treaty (“PCT”) filing application by February 28, 2018, for IGC-506, which is designed…

Continue Reading

FridayDec 08, 2017 11:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as…

Continue Reading

MondayDec 04, 2017 9:21 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

Major interest generated in Lexaria’s technology at MJBizCon Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050

PsychedelicNewsWire
PsychedelicNewsWire

1728 Ocean Ave
Suite PNW-276
San Francisco, CA 94112
(415) 949-5050

Copyright © . PsychedelicNewsWire / 1728 Ocean Ave, Suite PNW-276, San Francisco, CA 94112 (415) 949-5050 / Disclaimers